Status:
COMPLETED
Effect of Nusinersen on Adults With Spinal Muscular Atrophy
Lead Sponsor:
Northwell Health
Conditions:
Adult Spinal Muscular Atrophy
Eligibility:
All Genders
18-60 years
Brief Summary
Observational study of adult patients with spinal muscular atrophy types 2 and 3 receiving nusinersen
Detailed Description
Observational study to assess effects of nusinersen on motor function in adult patients with spinal muscular atrophy who are both ambulatory and non-ambulatory. Subjects will receive standard of care ...
Eligibility Criteria
Inclusion
- Genetically confirmed 5q SMA
- ability to access intrathecal space for nusinersen injection
Exclusion
- Renal impairment
- thrombocytopenia
- inability to access intrathecal space by CT or flouro guided injection
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 13 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03878030
Start Date
April 1 2019
End Date
July 13 2021
Last Update
March 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwell Health Neuroscience
Great Neck, New York, United States, 11021